DVA vs THC
DaVita and Tenet Healthcare Corporation, both Healthcare
Tenet Healthcare Corporation is the larger company at $22B against $12B. On trailing earnings THC is the cheaper of the two at a P/E of 10.5 against 14.9, a gap that is only a bargain if the two are growing at similar rates. Over the past year DVA returned +38% against +33% for THC. The RyuScore puts THC ahead, 78 against 72 out of 100.
| Figure | DVA | THC |
|---|---|---|
| Last close | $181 | $272 |
| Market cap | $12B | $22B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 14.9 | 10.5 |
| 1-year return | +38% | +33% |
| 5-year return | +55% | +309% |
| RyuScoresector-relative, 1–10 | 72/100 | 78/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
DaVita
Revenue of $3.6B in Q2 2026, net income $265M. Its largest reported line is U.S.Dialysis With Intersegment, 56% of the disclosed total.
Tenet Healthcare Corporation
Revenue of $5.6B in Q2 2026, net income $1.0B. Its largest reported line is Health Care Patient Service Managed Care, 44% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.